> Products > CAS NO 3976-69-0

China CAS NO 3976-69-0 Factory

Assume full responsibility to satisfy all needs of our clients; achieve continual advancements by endorsing the expansion of our purchasers; turn into the final permanent cooperative partner of clientele and maximize the interests of clients for CAS NO 3976-69-0,3976-69-0,Dorzolamide intermediate,Dorzolamide advance intermediate,Methyl (R)-(-)-3-hydroxybutyrate, Customers' profit and pleasure are constantly our biggest goal. You should contact us. Give us a probability, offer you a surprise.
CAS NO 3976-69-0, Our mission is "Provide Merchandise with Reliable Quality and Reasonable Prices". We welcome customers from every corner of the world to contact us for future business relationships and achieving mutual success!

Hot Products

(S)-(+)-2-Phenylglycinol
Product Name:(S)-(+)-2-Phenylglycinol
Molecular Formula:C8H11NO
Molecular Weight:137.18
CAS Registry Number:20989-17-7
L-Leucine benzyl ester p-toluenesulfonate salt
Product Name:L-Leucine benzyl ester p-toluenesulfonate salt
Molecular Formula:C20H27NO5S
Molecular Weight:393.5
CAS Registry Number:1738-77-8
Benzoic acid, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-, Methyl ester
Product Name:Benzoic acid, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-, Methyl ester
Molecular Formula:C16H11FN2O3
Molecular Weight:298.27
CAS Registry Number:775304-60-4
Eldecalcitol Intermediate A-TBDPS
Product Name:Eldecalcitol Intermediate A-TBDPS
Molecular Formula:C52H75O5PSi3
Molecular Weight:895.38
CAS Registry Number:1254276-84-0
4-Chloropyridinium chloride
Product Name:4-Chloropyridinium chloride
Molecular Formula:C5H5Cl2N
Molecular Weight:150.01
CAS Registry Number:7379-35-3
Vindoline
Product Name:Vindoline
Molecular Formula:C25H32N2O6
Molecular Weight;456.53
CAS Registry Number;2182-14-1

Related Blog
Reviews

FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC
On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
Why API manufacturing companies almostly in China?
In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...
Development Trend of China's Pharmaceutical Intermediate Industry
The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.
Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry
Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.
Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?
API is fundamental to the modern drug manufacturing process and cutting cost should not be the only criteria that can be applied to the production of an active pharmaceutical ingredient as it can adversely affect human health if the above-mentioned regulations and practices are not followed strictly.
Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS
Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

China CAS NO 3976-69-0 Factory

Related Products

Hot Products

(S)-(+)-2-Phenylglycinol

L-Leucine benzyl ester p-toluenesulfonate salt

Benzoic acid, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-, Methyl ester

Eldecalcitol Intermediate A-TBDPS

4-Chloropyridinium chloride

Vindoline

FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

Why API manufacturing companies almostly in China?

Development Trend of China's Pharmaceutical Intermediate Industry

Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

Cherry 2022-08-24 12:25:25

Jessie 2023-04-18 07:10:35

Eleanore 2023-06-11 03:08:05

Novia 2024-01-22 19:34:43

Bertha 2022-08-13 10:53:56

Nydia 2023-01-30 14:03:01

Send Inquiry